Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
- 1 December 2020
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 320, 78-82
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive SummaryJACC, 2014
- Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillationThrombosis and Haemostasis, 2014
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial FibrillationStroke, 2013
- Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategiesThrombosis and Haemostasis, 2013
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial FibrillationJACC, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Atrial Fibrillation: A Major Contributor to Stroke in the ElderlyArchives of internal medicine (1960), 1987